What should I know about Argenx?
Argenx is a commercial-stage biotechnology company that develops treatments for autoimmune diseases, in which the immune system attacks the body's own tissue. It is registered in the Netherlands and has major operations in Belgium. Its main medicine, Vyvgart, works by lowering levels of harmful antibodies. The company describes itself as a commercial-stage biopharma company and has about 1,863 full-time employees. In the second quarter of 2026 it reported total operating income, which includes product sales, of $1.542 billion, compared with $967 million a year earlier.
What are Argenx's main drugs?
Argenx's main products are Vyvgart and Vyvgart Hytrulo (efgartigimod), approved for generalised myasthenia gravis, a condition that causes muscle weakness. Global net sales of Vyvgart were $1.516 billion in the second quarter of 2026, up 60% on a year earlier, and $2.813 billion for the first half. In the US the approved use now covers all types of generalised myasthenia gravis. The company made a net profit of $472 million in the second quarter and held $5.2 billion in cash and financial assets.
What is Argenx currently developing?
Argenx is testing efgartigimod and other candidates in further autoimmune diseases. Results from its Phase 3 myositis study (ALKIVIA) are expected in the third quarter of 2026, and from the empasiprubart study in multifocal motor neuropathy (EMPASSION) in the fourth quarter. Primary immune thrombocytopenia results are due in the first half of 2027 and Sjögren's disease results in the second half of 2027. The company's "Vision 2030" aims to treat 50,000 patients, win 10 labelled indications and move five candidates into registrational development.
Is Argenx publicly traded, and how big is it?
Yes. Argenx is listed on the Nasdaq under the ticker ARGX, and its shares also trade on Euronext Brussels. Its market value was about $58 billion in autumn 2026, with the shares at about $933, within a 52-week range of $662 to $1,073. It is profitable: first-half 2026 net profit was $838 million on total operating income of $2.854 billion. It is due to report its next results on 22 October 2026.